Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MF-only Clear all
Completed Phase 1 Interventional

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496
View directory record Official record
Conditions
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
Interventions
Tinostamustine
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 3, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
View directory record Official record
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 3, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870
View directory record Official record
Conditions
Myelofibrosis
Interventions
Selinexor, Physician's Choice Treatment
Drug · Other
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Pasadena, California • Aurora, Colorado • Niles, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Classroom Break, Cognition, and Fitness in Elementary School Children

NCT06258941
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MF-HIIT, HIIT-only, MF-only, Sedentary activity
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
8 Years to 12 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Royal Center, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting Phase 1 Interventional

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

NCT06834282
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
CER-1236, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
CERo Therapeutics Holdings, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Sacramento, California • Denver, Colorado • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting Phase 2 Interventional

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

NCT04256018
View directory record Official record
Conditions
Sezary Syndrome, Mycosis Fungoides
Interventions
Mogamulizumab, LD TSEBT
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-88549968, Ruxolitinib, Momelotinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)

NCT06507189
View directory record Official record
Conditions
Aging, Aging Well
Interventions
Combined endurance and resistance training
Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
60 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Pensacola, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

NCT03144687
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Itacitinib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tempe, Arizona • Orange, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

NCT06327100
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
Interventions
Ruxolitinib, Tasquinimod
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

NCT02226172
View directory record Official record
Conditions
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions
Glasdegib (PF-04449913), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161
View directory record Official record
Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 3, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components

NCT00453297
View directory record Official record
Conditions
Healthy
Interventions
MF101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2008 · Synced Sep 3, 2026, 1:22 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

NCT00360035
View directory record Official record
Conditions
Myelofibrosis
Interventions
Obatoclax mesylate (GX15-070MS)
Drug
Lead sponsor
Gemin X
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gingival Retraction for Digital Scan Data

NCT07119281
View directory record Official record
Conditions
Data Accuracy, Bleeding Control
Interventions
Group A: Cordless paste with astringent (EXP): Expasyl (Acteon PVT LTD), Group B: Cordless paste without astringent (MF): Magic FoamCord (Coltene Whaledent AG), Group C: Laser troughing (LT): Diode laser (iLase; Biolase Inc.), Group D: Retraction cord with astringent (RCA; Control group): Knitted cord impregnated with aluminum chloride (Ultrapak + Viscostat Clear; Ultradent Inc.)
Procedure
Lead sponsor
Istanbul University
Other
Eligibility
25 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Media Based Motivational Intervention to Prevent Alcohol Exposed Pregnancies (AEPs)

NCT00219336
View directory record Official record
Conditions
Alcohol Consumption, Fetal Alcohol Syndrome Disorders, Students
Interventions
Self-guided Motivational Intervention, Informational Only
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 3, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04480086
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Mivebresib, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 3, 2026, 1:22 PM EDT
Recruiting No phase listed Observational

Abbott Structural Heart Device Registry

NCT06590467
View directory record Official record
Conditions
Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions
Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

NCT01445769
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Highland, California • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 3, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

NCT03755518
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
FEDRATINIB
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 3, 2026, 1:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

NCT01187446
View directory record Official record
Conditions
Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Interventions
Total skin electron beam therapy (TSEBT), Vorinostat
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Stanford, California • New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 3, 2026, 1:22 PM EDT
Completed No phase listed Observational

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
114
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 3, 2026, 1:22 PM EDT